Improved insulin absorption for diabetes sufferers

New technology for improved absorption of certain proteins and macromolecules within the gastrointestinal (GI) tract promises to greatly enhance insulin compliance among diabetes sufferers. Coremed's proprietary in vivo encapsulation (IVE) technology is a physiochemically triggered drug delivery system within the GI tract that is designed to overcome variables regarding physical barriers, digestive states, hydration status, membrane permeability, enzymatic degradation, and transit and peristaltic movement.Currently, the company is putting its Intesulin oral insulin through a series of proof-of-principle human trials. Trial II, which uses IVE will be compared with Trial I.

www.coremedusa.com